China
Africa
Explore chapters and articles related to this topic
Potential of Pseudocereals in Celiac Disease
Published in Megh R. Goyal, Preeti Birwal, Durgesh Nandini Chauhan, Herbs, Spices, and Medicinal Plants for Human Gastrointestinal Disorders, 2023
Caterina Anania, Francesca Olivero
CD is found in subjects with a genetic predisposition and results from environmental components. The presence of HLA-DQ2 and -DQ8 constitute a necessary but not a sufficient explanation for the occurrence of the disorders, and the development of the disease requires gluten ingestion as a further necessary factor. The toxic fractions of gluten are gliadins, which contain large amount of proline and glutamine and are incompletely digested. Certain gliadin peptides manage to cross the intestinal barrier and thereby make their way into the lamina propria of the small intestine via tight junctions of transcellular and paracellular routes.
Contact Dermatitis
Published in Pudupakkam K Vedanthan, Harold S Nelson, Shripad N Agashe, PA Mahesh, Rohit Katial, Textbook of Allergy for the Clinician, 2021
The prognosis of CD depends on a multitude of factors including identification of the relevant allergen and ease of avoidance of that allergen. Allergens such as fragrance and preservatives are encountered frequently in daily life and are more difficult to avoid. Products labeled as ‘fragrance free’ are generally safe to use in patients with fragrance allergy; unscented and hypoallergenic products may still include low levels of fragrance used to mask an odor (Marks et al. 2002).
Low-Dose Naltrexone
Published in Sahar Swidan, Matthew Bennett, Advanced Therapeutics in Pain Medicine, 2020
There are between 18,000 to 45,000 new cases of Crohn’s disease (CD), a subset of inflammatory bowel disease, each year in the United States. Crohn’s disease has a dual peak incidence often occurring between the ages of 20–30 and 60–70, with females being 20–30% more likely to develop CD than males. The signs and symptoms of CD are highly variable, but patients typically present with diarrhea and abdominal pain. Additional symptoms can include hematochezia, perirectal lesions, and perianal lesions.
Promising phase II biologics for future Crohn’s disease therapy
Published in Expert Opinion on Investigational Drugs, 2023
Pauline Wils, Silvio Danese, Laurent Peyrin-Biroulet
In IBD, randomized controlled trials are still growing [59]. Despite new biologic therapies, most CD patients will require surgery during their lifetime, and many will require multiple operations [60,61]. So, there is an important issue in the treatment of moderate-to-severe CD, to prevent disease progression, CD complications, and surgery. In parallel, in recent years, recruitment difficulties into randomized clinical trials have been observed, partly due to the increased number of demands in IBD [62]. Increased understanding of the pathophysiology of IBD has led to the development of new targeted therapies and opens future perspectives in the management of CD patients. This review highlights some emerging biologics, with new mechanisms of action, including IL-23p19 inhibitors, IL-6 inhibitors, and therapies interfering with T-cell trafficking (anti-MAdCAM-1).
Vitiligo and Crohn′s disease form an autoimmune cluster: insights from a population-based study
Published in Scandinavian Journal of Gastroenterology, 2023
Khalaf Kridin, Daniel Goral, Wesal Shihade, Dana Tzur-Bitan, Erez Onn, Lilach Zoller, Arnon D. Cohen
Crohn’s disease (CD) is a relapsing systemic inflammatory disease affecting the gastrointestinal tract, from the mouth to the anus [11]. In CD, the immune system goes out of balance, presumably while trying to defend itself from microbial antigens [12,13]. Together with ulcerative colitis, the prevalence of inflammatory bowel disease (IBD) has reached over 0.3% in the western world, while its incidence in the industrialized world is continuously growing [14–17]. CD is a leading cause of colovesical fistula and imposes an increased risk of intestinal malignancies [18,19]. Although there is no cure for CD, there are therapeutic options to induce remission, and certain lifestyles were proved beneficial in mitigating the activity of the disease [11,20]. CD was found to coexist with a wide array of autoimmune diseases [21].
An upper cervical spine treatment protocol for cervicogenic dizziness: a randomized controlled trial
Published in Physiotherapy Theory and Practice, 2022
Andoni Carrasco-Uribarren, Jacobo Rodríguez-Sanz, Carlos López-de-Celis, Pablo Fanlo-Mazas, Sara Cabanillas-Barea
The pathophysiology of CD is controversial among clinicians and scientists, but it seems that manual therapy helps reduce the symptoms and signs of these subjects (Yaseen et al., 2018). The neurophysiological effects of manual therapy in CD are uncertain. The hypoalgesic effects of manual therapy in the cervical spine might work similarly for CD. Decreasing pain could improve the range of motion of the cervical spine with or without gaze fixed. These improvements could normalize the sensorimotor input, producing a reduction in the dizziness sensation. This would explain the decrease in the intensity of dizziness and in patients’ self-perceived disability. More studies are needed to define hypoalgesic effects in these subjects. Additionally, it would be necessary to refine the dose and time of treatment for the approach to be more effective.